New antibodies may lead to a norovirus vaccine

The antibodies work against a variety of norovirus strains.

Norovirus, sometimes called “stomach flu” or the “winter vomiting bug,” infects 20 million Americans a year, making it the number one cause of food poisoning and one of the most common infectious diseases in the U.S.

The disease is miserable, and the virus is extremely contagious. In spite of this, there’s no treatment and no norovirus vaccine. The virus has dozens of strains, which are all constantly mutating, and it provokes only short-term natural immunity. 

It’s a nearly impossible target for a vaccine.

But now, researchers at Vanderbilt and Baylor College of Medicine have identified antibodies that shut down a broad range of norovirus strains that have long vexed vaccine efforts. 

“We were surprised to find naturally occurring antibodies that recognized so many different noroviruses,” James Crowe Jr, professor of Pediatrics and Pathology, Microbiology & Immunology at Vanderbilt University Medical Center, said in a release.

“Previously, many experts thought that this would not be possible because of the extreme sequence diversity in the various groups and types of noroviruses in circulation. The human immune system continues to surprise us in its capacity to recognize diverse virus variants.”

Nasty norovirus: Looking like a buzz-cut coronavirus, norovirus is a fiendishly infectious pathogen, which takes aim at the gastrointestinal tract. 

According to the CDC, the virus spreads easily and quickly from people and tainted foods/surfaces, leaving excretory havoc in its wake: nausea, vomiting, diarrhea, and stomach pain are all hallmarks of norovirus. It can be washed down the drain, but it’s very hard to kill with disinfectants.

As the leading cause of foodborne illness in the U.S., the CDC estimates that norovirus sends 19-21 million genuflectors to the porcelain throne per year, even killing around 900 people.

So, yeah, a norovirus vaccine would be pretty nice. 

Norovirus is the #1 cause of food poisoning, sending about 20 million Americans scrambling for the bathroom per year.

Unfortunately, this is easier said than done. The virus is “constantly evolving, evoking limited immunity, and only moderately virulent, allowing most of those infected to fully recover, thereby maintaining a large susceptible pool of hosts,” the CDC’s Aron J. Hall wrote in The Journal of Infectious Diseases

For him, norovirus may even lay claim to the title of “perfect human pathogen.” (One imagines this is a hotly contested award in viral circles.)

Towards a norovirus vaccine: The key to a good vaccine is finding antibodies that can neutralize a broad range of different virus strains. Once you know what you need to create, you can design a vaccine to prod the immune system into creating enough of it to stop the infection.

But norovirus is almost impossible to study, because it won’t grow in the lab. Before they could do anything to make a vaccine, researchers at Baylor College of Medicine had to invent a way to grow the virus outside of the body (because, uh, growing it inside is no fun).

Then in 2018, according to the Knoxville News Sentinel, they joined with Vanderbilt to harvest white blood cells from people who recently had a norovirus infection. These immune cells would normally die off, but Vanderbilt has a technique to fuse them with cancer cells, which allows them to keep growing indefinitely.

Norovirus is currently a nearly impossible target for a vaccine.

“Two inventions just happened around the same time,” Crowe told the News Sentinel. “We put the two together.”

By pitting Baylor’s lab-grown viruses against Vanderbilt’s cloned immune cells, the team could simulate infections and generate a ton of antibodies in the lab — which they can sort through to find the perfect weapon against norovirus.

Stomach flu kryptonite: The newly identified antibodies, reported in Nature Communications in July, recognize numerous types of noroviruses. Pulling from subjects with a history of acute gastroenteritis, the researchers were able to identify a panel of monoclonal antibodies. 

These antibodies take aim at part of the virus that is common to all of the different strains and rarely mutates — a slower moving target that could be a good candidate for a norovirus vaccine. 

“It is exciting to now have human monoclonal antibodies that neutralize many norovirus variants,” Mary Estes, professor of virology at Baylor College, said in the release.

In addition to helping identify norovirus vaccine candidates, the monoclonal antibodies could potentially be used directly to prevent or treat norovirus infection, the researchers say.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Revolutionary weight-loss drugs like Wegovy come with a catch
People taking GLP-1 agonists are losing too much muscle, but these drugs designed to prevent muscle loss could solve the problem.
Are weight-loss meds the next wonder drugs?
Evidence is mounting that GLP-1 agonists could treat many health issues — including ones that aren’t obviously related to weight.
Milk could overcome one of the biggest hurdles to RNA therapies
RNA therapies typically break down if administered orally, but particles found in cows’ milk could provide perfect protection.
Last century, we extended our lives. This century, we need to shorten our deaths.
We are living longer lives, while also spending more years sick than ever before — but there are ways to close the lifespan-healthspan gap
See how Moderna is using OpenAI tech across its workforce
A partnership between Moderna and OpenAI provides a real-world example of what can happen when a company leans into generative AI.
Up Next
Subscribe to Freethink for more great stories